Roche still awaiting Tecentriq survival data in key study


ZURICH (Reuters) – Roche’s Tecentric immunotherapy mixed with chemotherapy has not yet achieved a hoped-for overall survival target in first-line lung cancer treatment, the Swiss drugmaker said on Thursday.

FILE PHOTO: The logo of Swiss pharmaceutical company Roche is pictured on the company’s headquarters in Basel February 4, 2009. REUTERS/Christian Hartmann (SWITZERLAND)/File Photo

The Tecentriq combination with pemetrexed in non-small

cell lung cancer (NSCLC) did reduce the risk of the disease worsening or death, the Swiss drugmaker said.

The Basel-based company is still waiting for…



Read More Here

Be the first to comment on "Roche still awaiting Tecentriq survival data in key study"

Leave a comment

Your email address will not be published.


*